<code id='AA388A9309'></code><style id='AA388A9309'></style>
      • <acronym id='AA388A9309'></acronym>
      <center id='AA388A9309'><center id='AA388A9309'><tfoot id='AA388A9309'></tfoot></center><abbr id='AA388A9309'><dir id='AA388A9309'><tfoot id='AA388A9309'></tfoot><noframes id='AA388A9309'>
      • <optgroup id='AA388A9309'><strike id='AA388A9309'><sup id='AA388A9309'></sup></strike><code id='AA388A9309'></code></optgroup>
        5. <b id='AA388A9309'><label id='AA388A9309'><select id='AA388A9309'><dt id='AA388A9309'><span id='AA388A9309'></span></dt></select></label></b><u id='AA388A9309'></u>
          <i id='AA388A9309'><strike id='AA388A9309'><tt id='AA388A9309'><pre id='AA388A9309'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-09-28 02:11:03 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：fashion   
                                        
                                      
                                      Page View：1596
                                  
                                    
          
                                   
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP
          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.
          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.
          advertisement
          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          A letter from the executive editor: STAT UnitedHealth investigation
                                
                            
          Next article：  
                                      
                                          Drug repurposing or repositioning? The language matters
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles